- Rapport Therapeutics announced issuance of 2.25% convertible senior notes due 2032.
- Dilution risk from convertible structure and Item 3.02 unregistered sales/private placement.
- Estimated cash and short-term investments stood at approximately $395.0M as of September 30.
?? Negative AI Sentiment (-2.0 / 10)